Decheng Capital LLC Lyell Immunopharma, Inc. Transaction History
Decheng Capital LLC
- $466 Billion
- Q4 2024
A detailed history of Decheng Capital LLC transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Decheng Capital LLC holds 11,909,341 shares of LYEL stock, worth $7.26 Million. This represents 1.63% of its overall portfolio holdings.
Number of Shares
11,909,341Holding current value
$7.26 Million% of portfolio
1.63%Shares
1 transactions
Others Institutions Holding LYEL
# of Institutions
107Shares Held
171MCall Options Held
7.7KPut Options Held
15.3K-
Mwg Management Ltd. Washington, DC20.2MShares$12.3 Million17.35% of portfolio
-
Apoletto LTD Washington, DC15.1MShares$9.21 Million42.56% of portfolio
-
Orland Properties LTD Washington, DC15.1MShares$9.21 Million14.08% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$8.23 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.77MShares$5.96 Million0.0% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $151M
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...